Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for CTNM
Across the 16 sessions after earlier CTNM headlines, the stock closed higher 12 times and lower 4 times, with a median move of 4.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CTNM | SPY |
|---|---|---|---|
| May 13, 2026 | Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference | +3.6% | +0.6% |
| May 12, 2026 | Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference | +0.1% | -0.2% |
| May 6, 2026 | Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | +3.8% | +1.4% |
| May 4, 2026 | Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +7.2% | -0.4% |
| May 1, 2026 | Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain | +3.0% | +0.3% |
| Mar 16, 2026 | Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +2.8% | +1.0% |
Quantisnow market dataNASDAQ
CTNM
Contineum Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for CTNM
Full CTNM profile on Quantisnow Follow CTNM and get a push notification the moment its next story breaks.